Not yet taking people in SpainPhase 2
Testing Endoret eye drops on the eye surface in people with glaucoma
Tests Endoret eye drops in adults with glaucoma treated with eye pressure drugs.
Key facts
- Who runs it
- Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
- Where
- Barcelona, SpainSee the site
- Registry title
- Evaluation of the regenerative efficacy of Endoret® (PRGF-Plasm Rich in Growth Factors) on the ocular surface of glaucoma patients treated chronically with ocular hypotensive drugs, Evaluación de la eficacia regenerativa de Endoret® (PRGF-Plasma Rico en Factores de Crecimiento) en la superficie ocular de pacientes glaucomatosos tratados de forma crónica con fármacos hipotensores oculares
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 22 Jan 2025
- Planned end
- 22 Jan 2026
- Type of study
- Interventional
- Record updated
- 29 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with glaucoma who have used at least two preservative-free eye pressure drops (3 drops a day) for at least two years.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Glaucoma, treated with at least two ocular hypotensive drugs (3 drops a day), without preservatives, for at least the last two years.
- Earlier treatment
- Must have used at least two ocular hypotensive drugs without preservatives for a minimum of two years. Cannot have used topical blood derivatives in the last 6 months or had eye surface surgery.
Main reasons for not taking part
- Eye surface disease other than toxicity from the ocular hypotensive drugs
- Previous eye surface surgery
- Topical blood derivative treatment in the last 6 months
- Pregnant or breastfeeding women, or women of childbearing age who intend to become pregnant
- Allergy to local anesthetics
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adult patients diagnosed with glaucoma who are undergoing treatment with at least two ocular hypotensive drugs (3 drops/day) without preservatives for a minimum of the last two years and who consent to participate in the study
Who cannot take part
- Ocular surface pathology other than toxicity due to ocular hypotensive drugs
- Previous ocular surface surgeries
- Treatment with topical blood derivatives in the last 6 months
- Allergy to local anesthetics
- Women of childbearing age with pregnancy intention, pregnant women, and breastfeeding women
Where in Spain
- Hospital de la Santa Creu i Sant PauBarcelona, SpainNot yet recruiting
About the trial
What the trial wants to find out
To assess the changes in tear osmolarity after topical treatment with PRGF.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Evaluation of the regenerative efficacy of Endoret® (PRGF-Plasm Rich in Growth Factors) on the ocular surface of glaucoma patients treated chronically with ocular hypotensive drugs, Evaluación de la eficacia regenerativa de Endoret® (PRGF-Plasma Rico en Factores de Crecimiento) en la superficie ocular de pacientes glaucomatosos tratados de forma crónica con fármacos hipotensores oculares
- Plain-language title
- Testing Endoret eye drops on the eye surface in people with glaucomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 29 January 2025